WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H527907
CAS#: 104146-53-4 (sodium)
Description: Cefditoren sodium, also known as ME-1206 and Cefditoren, is a cephalosporin antibiotic potentially for the treatment of bacterial infection. The expression levels of Mrp2, Bcrp, Oat2 mRNA were markedly increased, while P-gp and Oct1 mRNA were decreased. In concordance with RT-PCR results, Mrp2 expression level increased by Western blotting. These results indicate that Mrp2 and Bcrp may be involved in the biliary excretion of cefditoren. Cefditoren can up-regulate the expression levels of Mrp2, Bcrp and Oat2, and down-regulate P-gp and Oct1 mRNA expression.
Hodoodo Cat#: H527907
Name: Cefditoren sodium
CAS#: 104146-53-4 (sodium)
Chemical Formula: C19H17N6NaO5S3
Exact Mass: 0.00
Molecular Weight: 528.552
Elemental Analysis: C, 43.18; H, 3.24; N, 15.90; Na, 4.35; O, 15.13; S, 18.20
Related CAS #: 104146-53-4 (sodium) 104145-95-1 (free base) 117467-28-4 (pivoxil) 442852-27-9 (tosylate) 442852-31-5 (oxalate) 442852-33-7 (sulfate) 1448435-17-3 (HCl) 442852-29-1 (mesylate)
Synonym: Cefditoren sodium; Cefditoren; Cefditoren pivoxil; ME 1206; ME-1206; ME1206
IUPAC/Chemical Name: sodium (6R,7R)-7-((E)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((Z)-2-(4-methylthiazol-5-yl)vinyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
InChi Key: VFUMWBZIKOREOO-DKRMNOTNSA-M
InChi Code: InChI=1S/C19H18N6O5S3.Na/c1-8-11(33-7-21-8)4-3-9-5-31-17-13(16(27)25(17)14(9)18(28)29)23-15(26)12(24-30-2)10-6-32-19(20)22-10;/h3-4,6-7,13,17H,5H2,1-2H3,(H2,20,22)(H,23,26)(H,28,29);/q;+1/p-1/b4-3-,24-12+;/t13-,17-;/m1./s1
SMILES Code: O=C(C(N12)=C(/C=C\C3=C(C)N=CS3)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N/OC)=O)C1=O)[O-].[Na+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 528.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Sadahira T, Wada K, Araki M, Ishii A, Takamoto A, Kobayashi Y, Watanabe M, Watanabe T, Nasu Y, Kumon H; Okayama Urological Research Group (OURG).. Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: multicentre, randomized, open-label trial. J Antimicrob Chemother. 2017 Feb;72(2):529-534. doi: 10.1093/jac/dkw424. PubMed PMID: 27733519.
2: Ulloa C, Guevara S, Soley C, Abdelnour A, Arguedas A. In vitro Activity of Cefditoren against Middle Ear Fluid Isolates from Costa Rican Children with Otitis Media. Chemotherapy. 2014;60(4):211-8. doi: 10.1159/000371836. PubMed PMID: 25871785.
3: Di Marco F, Braido F, Santus P, Scichilone N, Blasi F. The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung inflammation and epithelial damage. Eur Rev Med Pharmacol Sci. 2014;18(3):321-32. Review. PubMed PMID: 24563430.
4: Gawande VT, Bothara KG, Singh A, Mahajan AA. Identification and Characterization of Hydrolytic Degradation Products of Cefditoren Pivoxil using LC and LC-MS/TOF. Indian J Pharm Sci. 2015 Jan-Feb;77(1):75-82. PubMed PMID: 25767321; PubMed Central PMCID: PMC4355885.
5: Hatzaki D, Poulakou G, Katsarolis I, Lambri N, Souli M, Deliolanis I, Nikolopoulos GK, Lebessi E, Giamarellou H. Cefditoren: Comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients. BMC Infect Dis. 2012 Sep 25;12:228. doi: 10.1186/1471-2334-12-228. PubMed PMID: 23009290; PubMed Central PMCID: PMC3518207.
6: Soriano F, Giménez MJ, Aguilar L. Cefditoren in upper and lower community-acquired respiratory tract infections. Drug Des Devel Ther. 2011 Feb 9;5:85-94. doi: 10.2147/DDDT.S9499. Review. PubMed PMID: 21340042; PubMed Central PMCID: PMC3038999.
7: Yang Q, Xu Y, Chen M, Wang H, Sun H, Hu Y, Zhang R, Duan Q, Zhuo C, Cao B, Liu Y, Yu Y, Sun Z, Chu Y. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China. Diagn Microbiol Infect Dis. 2012 Jun;73(2):187-91. doi: 10.1016/j.diagmicrobio.2012.03.005. PubMed PMID: 22521692.
8: Blasi F, Tarsia P, Mantero M, Morlacchi LC, Piffer F. Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication. Ther Clin Risk Manag. 2013;9:55-64. doi: 10.2147/TCRM.S41131. PubMed PMID: 23430960; PubMed Central PMCID: PMC3575210.
9: Cafini F, Aguilar L, Alou L, Giménez MJ, Sevillano D, Torrico M, González N, Coronel P, Prieto J. Cefditoren versus ceftazidime in inducer-substrate combinations for the evaluation of AmpC production in a disc approximation test. Rev Esp Quimioter. 2010 Jun;23(2):72-5. PubMed PMID: 20559604.
10: Meng Q, Liu Q, Wang C, Sun H, Kaku T, Kato Y, Liu K. Molecular mechanisms of biliary excretion of cefditoren and the effects of cefditoren on the expression levels of hepatic transporters. Drug Metab Pharmacokinet. 2010;25(4):320-7. PubMed PMID: 20814152.
11: Cuevas O, Cercenado E, Gimeno M, Marín M, Coronel P, Bouza E; Spanish Urinary Tract Infection Study Group (SUTIS).. Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study. Diagn Microbiol Infect Dis. 2010 Jul;67(3):251-60. doi: 10.1016/j.diagmicrobio.2010.02.013. PubMed PMID: 20542206.
12: Tempera G, Furneri PM, Carlone NA, Cocuzza C, Rigoli R, Musumeci R, Pilloni AP, Prenna M, Tufano MA, Tullio V, Vitali LA, Nicoletti G. Antibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on cefditoren. J Chemother. 2010 Jun;22(3):153-9. PubMed PMID: 20566418.
13: Zhang Q, Liu Q, Wu J, Wang C, Peng J, Ma X, Liu K. PEPT1 involved in the uptake and transepithelial transport of cefditoren in vivo and in vitro. Eur J Pharmacol. 2009 Jun 10;612(1-3):9-14. doi: 10.1016/j.ejphar.2009.03.081. PubMed PMID: 19371738.
14: Biedenbach DJ, Jones RN. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations. Diagn Microbiol Infect Dis. 2009 Jun;64(2):202-12. doi: 10.1016/j.diagmicrobio.2009.01.017. Review. PubMed PMID: 19321284.
15: Kang JH, Lee SY, Kim JH, Hur JK, Lee KY. In vitro antimicrobial activity of cefditoren and other oral antibiotics against Streptococcus pneumoniae, isolated from children with community acquired respiratory tract infections. Jpn J Antibiot. 2010 Feb;63(1):11-7. PubMed PMID: 20836403.
16: Seral C, Suárez L, Rubio-Calvo C, Gómez-Lus R, Gimeno M, Coronel P, Durán E, Becerril R, Oca M, Castillo FJ. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain. Diagn Microbiol Infect Dis. 2008 Oct;62(2):210-5. doi: 10.1016/j.diagmicrobio.2008.06.007. PubMed PMID: 18715733.
17: Granizo JJ, Aguilar L, Gimenez MJ, Coronel P, Gimeno M, Prieto J. Safety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infections. Rev Esp Quimioter. 2009 Jun;22(2):57-61. PubMed PMID: 19544097.
18: Manaktala C, Singh AK, Verma M, Sachdeva A, Sharma H, Roy A, Jalali RK, Gowrishankar R, Kumar A, Kumar AS, Jayaraman AM, Swarnkar B, Srinivas CR, Nayak C, Duttaroy D, Umrigar D, Jesudanam M, Maheshwari N, Shetty P, Singh RP, Ghate S, Sacchidanand S, Tolat S, Bhoira S, Marfatia Y. Efficacy and tolerability of cefditoren pivoxil in uncomplicated skin and skin structure infections in Indian patients. Indian J Dermatol. 2009;54(4):350-6. doi: 10.4103/0019-5154.57612. PubMed PMID: 20101337; PubMed Central PMCID: PMC2807712.
19: Stefani S, Mezzatesta ML, Fadda G, Mattina R, Palù G, Rossano F, Tufano MA, Schito GC, Nicoletti G. Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy. J Chemother. 2008 Oct;20(5):561-9. PubMed PMID: 19028617.
20: Yamada M, Watanabe T, Miyara T, Baba N, Saito J, Takeuchi Y, Ohsawa F. Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity. Antimicrob Agents Chemother. 2007 Nov;51(11):3902-7. PubMed PMID: 17724158; PubMed Central PMCID: PMC2151468.
